Novavax has announced progress on a vaccine candidate targeting the avian influenza A(H5N1) virus, clade 2.3.4.4b. The vaccine aims to address pandemic threats arising from bird-to-human and human-to-human transmission of avian influenza strains. This advancement forms part of ongoing global efforts to develop effective prophylactics against emerging influenza viruses with pandemic potential, complementing existing vaccine strategies for seasonal and pandemic influenza.